Clinical trials: Plaque Psoriasis Subjects
Psoriasis
A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis
The purpose of the study is to assess the effect of extending maintenance dosing intervals beyond 12 weeks on the clinical efficacy and safety of ustekinumab in subjects with moderate-to-severe plaque psoriasis.
- Trial name
- PSTELLAR (NCT01550744)
- Testing
- Ustekinumab 45 mg, Ustekinumab 90 mg
- Where
- 40 sites in United States
- Volunteers
- 478 people
- Sponsor
- Janssen Biotech, Inc.
Chronic Plaque Psoriasis
Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment
The objective of this study is to assess the efficacy and safety of adalimumab in combination with topical psoriasis treatment, calcipotriol/betamethasone, vs.
- Trial name
- BELIEVE (NCT00574249)
- Testing
- adalimumab, Calcipotriol/Betamethasone Ointment
- Where
- 131 sites in Austria, Belgium and 13 more
- Volunteers
- 730 people
- Sponsor
- Abbott
Moderate-to-Severe Plaque Psoriasis
A Clinical Study to Compare the Safety and Pharmacokinetics of SHR-1314 Injection in Healthy Subjects at Different Specifications Devices
The purpose of this study is to evaluate the safety and pharmacokinetics of SHR-1314 injection in healthy subjects at different specifications devices.
- Trial name
- NCT06182384
- Testing
- SHR-1314
- Where
- China
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Psoriasis, Psoriatic Arthritis
Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis
This study will test the clinical effectiveness and safety of two orally administered doses of apremilast compared to placebo in Japanese patients with moderate-to-severe plaque-type psoriasis.
- Conditions
- Psoriasis, Psoriatic Arthritis, Psoriasis Arthropatica
- Trial name
- NCT01988103
- Testing
- Apremilast
- Where
- 56 sites in Japan
- Volunteers
- 254 people
- Sponsor
- Amgen
Psoriasis
Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis
The purpose of this research study is to compare the efficacy and safety of ABP 501 and adalimumab (HUMIRA®) in adults with plaque psoriasis.
- Trial name
- NCT01970488
- Testing
- Adalimumab, ABP 501
- Where
- 3 sites in Australia, Canada and 1 more
- Volunteers
- 350 people
- Sponsor
- Amgen
Plaque Psoriasis, Healthy Volunteer
A Study of UA026 Tablets in Healthy Adult Subjects and Adult Subjects With Moderate to Severe Plaque Psoriasis
This study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetic profile, and food effect of UA026 tablets.
- Trial name
- NCT07038720
- Testing
- UA026
- Where
- China
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Usynova Pharmaceuticals Ltd.
Plaque Psoriasis Vulgaris
Study to Assess the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of AZD0284 in Healthy Subjects
Plaque psoriasis vulgaris is a chronic inflammatory skin disorder, affecting 1-3% of the population in Europe and the United States of America (USA) and represents one of the most prevalent immune inflammatory diseases.
- Trial name
- NCT02976831
- Testing
- AZD0284
- Where
- United Kingdom
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Psoriasis
A Safety and Efficacy Study of DRM02 in Subjects With Plaque Psoriasis
The purpose of this study is to determine whether DRM02 is safe and effective in the treatment of plaque psoriasis when applied twice daily for 6 weeks.
- Trial name
- NCT01993433
- Testing
- DRM02, Vehicle
- Where
- 2 sites in Canada
- Volunteers
- 23 people
- Sponsor
- Dermira, Inc.
Psoriasis
The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis
The purpose of this research study is to compare the efficacy and safety of SCT630 and adalimumab (HUMIRA®) in adults with plaque psoriasis.
- Trial name
- NCT03927352
- Testing
- SCT630, Adalimumab
- Where
- China
- Volunteers
- 330 people
- Sponsor
- Sinocelltech Ltd.
Healthy Volunteers, Mild to Moderate Psoriasis
A First in Human Study of AX-202 in Healthy Subjects and Patients With Psoriasis.
The first-in-human study will be performed in healthy volunteers and patients with a chronic inflammatory skin disease. The primary objective is to evaluate the safety, tolerability and pharmacokinetics of increasing doses of…
- Trial name
- NCT05965089
- Testing
- AX-202
- Where
- United Kingdom
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Arxx Therapeutics
Moderate to Severe Plaque Psoriasis
A Phase 2 Clinical Study of KHK4827
This study is designed to evaluate the efficacy and safety of KHK4827 in subjects with moderate to severe plaque psoriasis in a randomized, double-blind, placebo-controlled, parallel group study.
- Trial name
- NCT01748539
- Testing
- KHK4827
- Where
- Japan
- Volunteers
- 140 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Plaque-Type Psoriasis
A Study to Evaluate the Efficacy and Tolerability of Topical Therapies for the Condition of Plaque-Type Psoriasis
The purpose of the study is to determine the efficacy and safety of two different forms of a topical steroid (clobetasol propionate) in patients with plaque-type psoriasis.
- Trial name
- NCT00852761
- Testing
- Olux-E Foam, Clobex lotion
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Stiefel, a GSK Company
Psoriasis
An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis
The objective of this Phase 2 trial is to determine the efficacy and safety of LYC-30937-EC in patients with moderate plaque-type psoriasis.
- Trial name
- NCT02872285
- Testing
- Drug: LYC-30937-EC
- Where
- 7 sites in United States
- Volunteers
- 33 people
- Sponsor
- Lycera Corp.
Psoriasis
Open-label Study to Evaluate Safety of Multiple Courses of IM Alefacept During Treatment of Chronic Plaque Psoriasis
An extension study to evaluate safety and tolerability of up to 3 additional courses of IM alefacept in patients with chronic plaque psoriasis who have been previously treated with 1 or 2 courses of IM alefacept.
- Trial name
- NCT00692172
- Testing
- Alefacept
- Where
- 43 sites in United States, Belgium and 7 more
- Volunteers
- 175 people
- Sponsor
- Astellas Pharma Inc
Psoriasis
Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis Two of Two Phase 3 Studies
The purpose of the study is to demonstrate the safety and efficacy of U0267 in subjects with plaque-type psoriasis.
- Trial name
- NCT00689481
- Testing
- U0267 Foam, Vehicle foam
- Where
- 12 sites in United States
- Volunteers
- 323 people
- Sponsor
- Stiefel, a GSK Company
Plaque Psoriasis
A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab
This study will evaluate whether adult participants with moderate to severe plaque psoriasis who have been treated with secukinumab or ixekizumab for at least 6 months and are experiencing a suboptimal response may benefit from…
- Trial name
- NCT04102007
- Testing
- Risankizumab
- Where
- 57 sites in United States, Australia and 6 more
- Volunteers
- 244 people
- Sponsor
- AbbVie
Chronic Plaque Psoriasis
Raptiva in Palm and Sole Psoriasis
The primary purpose of the study is to evaluate the safety and efficacy of Raptiva® compared to placebo in controlling moderate to severe chronic plaque psoriasis involving palms and/or soles scoring Palmo-plantar Pustular…
- Trial name
- NCT00972543
- Testing
- Efalizumab (Raptiva)
- Volunteers
- 6 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Psoriasis
Efficacy and Safety of Topical ALT-2074 (SYI-2074) for Treatment of Chronic Plaque Psoriasis
The primary objective of this study will be to evaluate the efficacy of topical ALT-2074 applied twice daily for 28 days for treatment of chronic plaque psoriasis in adult subjects.
- Trial name
- NCT00782613
- Testing
- 4,4-dimethyl-benziso-2H-selenazine
- Where
- 3 sites in Israel
- Volunteers
- 30 people
- Sponsor
- Synvista Therapeutics, Inc
Psoriasis
Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
The purpose of this study is to determine the effectiveness and safety, over 12 weeks, of 3 dosing regimens of CP-690,550 for the treatment of adults with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT00678210
- Testing
- CP-690,550
- Where
- 44 sites in United States, Canada
- Volunteers
- 197 people
- Sponsor
- Pfizer
Plaque Psoriasis, Skin Diseases
Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis
Study to evaluate the efficacy, safety, tolerability and pharmacokinetics of JTE-051 administered for 12 weeks in subjects with moderate to severe plaque psoriasis.
- Trial name
- CLEAR-PS (NCT03358290)
- Testing
- JTE-051
- Where
- 16 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- Shionogi Inc.